Clearance of Hepatitis C Virus After Fixed-Dose Combination Ledipasvir/Sofosbuvir in an Adolescent Female With Decompensated Cirrhosis

Corresponding Author

Sara K. Smith

[email protected]

Division of Pediatric Gastroenterology, Hepatology, and Nutrition, University of California, San Francisco

Address correspondence and reprint requests to Sara K. Smith, MD, Division of Pediatric Gastroenterology, Hepatology, and Nutrition, University of California, UCSF Box 0136 550 16th Str, 5th floor San Francisco, CA 94143 (e-mail: [email protected]).Search for more papers by this author

Philip Rosenthal,

Philip Rosenthal

Division of Pediatric Gastroenterology, Hepatology, and Nutrition, University of California, San Francisco

Search for more papers by this author

Sara K. Smith,

Corresponding Author

Sara K. Smith

[email protected]

Division of Pediatric Gastroenterology, Hepatology, and Nutrition, University of California, San Francisco

Philip Rosenthal,

Philip Rosenthal

Division of Pediatric Gastroenterology, Hepatology, and Nutrition, University of California, San Francisco

Search for more papers by this author

First published: 01 November 2016

https://doi.org/10.1097/MPG.0000000000001278

Citations: 4

The authors report no conflicts of interest.

Share a link

Email
Wechat
Bluesky

ABSTRACT

Currently the only Food and Drug Administration–approved treatment for children with chronic hepatitis C virus is pegylated interferon with ribavirin, which is associated with significant adverse effects and low sustained virologic response rates. In this report, we discuss the use of ledipasvir/sofosbuvir to treat an adolescent with cirrhosis secondary to chronic hepatitis C virus.

REFERENCES

1.Ohmer S, Honegger J. New prospects for the treatment and prevention of hepatitis C in children. Curr Opin Pediatr 2016; 28: 93–100.
10.1097/MOP.0000000000000313
CAS PubMed Web of Science® Google Scholar
2.Wirth S. Current treatment options and response rates in children with chronic hepatitis C. World J Gastroenterol 2012; 18: 99–104.
10.3748/wjg.v18.i2.99
CAS PubMed Web of Science® Google Scholar
3.Simmons B, Saleem J, Heath K, et al. Long term treatment outcomes of patients infected with hepatitis C virus: a systematic review and meta analysis of the survival benefit of achieving a sustained virological response. Clin Infect Dis 2015; 61: 730–740.
10.1093/cid/civ396
CAS PubMed Web of Science® Google Scholar
4.Kirby B. Adult doses of sofosbuvir plus ribavirin or ledipasvir/sofosbuvir provided comparable plasma exposures and tolerable safety profile in adolescents with hepatitis C virus (HCV) infection. Presented at: American Association for the Study of Liver Disease Annual Meeting; 2015; San Francisco, CA.
Google Scholar
5.Charlton M, Everson GT, Flamm SL, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 2015; 149: 649–659.
10.1053/j.gastro.2015.05.010
CAS PubMed Web of Science® Google Scholar
6.Gane EJ, Hyland RH, An D, et al. Sofosbuvir/ledipasvir fixed dose combination is safe and effective in difficult to treat populations including genotype 3 patients, decompensated type 3 patients and genotype 1 patients with prior sofosbuvir treatment experience. J Hepatol 2014; 60: S3–S4.
10.1016/S0168-8278(14)60008-8
Web of Science® Google Scholar

Citing Literature

Volume63, Issue5

November 2016

Pages 516-517

Clearance of Hepatitis C Virus After Fixed-Dose Combination Ledipasvir/Sofosbuvir in an Adolescent Female With Decompensated Cirrhosis

ABSTRACT

REFERENCES

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Clearance of Hepatitis C Virus After Fixed-Dose Combination Ledipasvir/Sofosbuvir in an Adolescent Female With Decompensated Cirrhosis

ABSTRACT

REFERENCES

Citing Literature

References

Related

Information